Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:2.7.7.48 (transcriptase)
 9,479 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

1. Kallikrein enzyme activity has been previously reported in the uterus of several species and implicated in implantation and parturition. In order to provide further evidence for a local kallikrein-kinin system in this tissue, we wished to determine if the gene encoding kallikrein (KLK1) was expressed in the human uterus and determine the pattern of its expression across the menstrual cycle. 2. Reverse-transcriptase polymerase chain reaction (RT-PCR) of endometrial and myometrial total RNA coupled with Southern blot analysis showed that KLK1 was expressed in the human endometrium and myometrium. Endometrial expression of KLK1 was confirmed by DNA sequence analysis of the PCR products. Kallikrein was also localized by immunocytochemistry, primarily in the glandular epithelium of the endometrium. 3. Quantitative RT-PCR of 37 endometrial samples ranging from day 1 to 29 from across the menstrual cycle showed significantly higher KLK1 (kallikrein) expression from the mid proliferative to the early secretory phase compared with the late secretory and menstrual phases. 4. We have demonstrated for the first time that KLK1, the gene encoding glandular kallikrein, is expressed in the human uterus. The increase in endometrial KLK1 gene expression during the proliferative phase of the menstrual cycle suggests a role for kallikrein in the preparation of the endometrial lining for implantation.
 ...
PMID:Glandular kallikrein gene expression in the human uterus. 774 74

The tissue kallikrein-kinin system is important in regulating cardiovascular and renal function, and dysregulation of the system has been implicated in heart and kidney pathologies. These findings suggest that if balance can be restored to the kallikrein-kinin axis, then associated disease progression may be attenuated. To test this hypothesis, recombinant adeno-associated virus (rAAV)-mediated human tissue kallikrein (HK) expression was induced in a rodent model of chronic renal failure involving 5/6 nephrectomy (nephrectomy plus 70% reduction of remaining kidney). rAAV-HK treatment attenuated the rise in blood pressure, glomerular sclerosis, and tubulointerstitial injury observed in this model. rAAV-HK treatment also attenuated renal function decline as measured by urinary microalbumin, osmolarity, and cGMP levels. Reverse transcriptase-polymerase chain reaction analysis showed that rAAV-HK-treated rats had higher levels of bradykinin receptor-2 (B(2)R) and dopamine receptor-1 mRNAs. In contrast, angiotensin II receptor-1, endothelin receptor-A, and vasopressin receptor-2 mRNAs were markedly downregulated in kidneys from HK-treated rats. Bradykinin induced similar changes in receptor levels and prevented transforming growth factor-beta(1)-induced tubulointerstitial fibrosis. The effects of bradykinin could be reversed with the B(2)R antagonist HOE-140. Together, these findings suggest that restoration of the kallikrein-kinin system reduces kidney injury and protects renal function in 5/6-nephrectomized rats via changes in the expression and activation of G protein-coupled receptors including B(2)R.
 ...
PMID:Delivery of recombinant adeno-associated virus-mediated human tissue kallikrein for therapy of chronic renal failure in rats. 1840 47